Y Intercept Hong Kong Ltd Lowers Holdings in Xeris Biopharma Holdings, Inc. $XERS

Y Intercept Hong Kong Ltd decreased its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 75.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,181 shares of the company’s stock after selling 254,033 shares during the period. Y Intercept Hong Kong Ltd owned approximately 0.05% of Xeris Biopharma worth $669,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. State of Alaska Department of Revenue purchased a new position in Xeris Biopharma in the third quarter worth about $68,000. Tower Research Capital LLC TRC raised its holdings in Xeris Biopharma by 913.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock worth $81,000 after acquiring an additional 15,678 shares during the last quarter. Modern Wealth Management LLC bought a new position in Xeris Biopharma in the 2nd quarter valued at approximately $83,000. Los Angeles Capital Management LLC purchased a new stake in Xeris Biopharma during the 2nd quarter valued at $95,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Xeris Biopharma in the 1st quarter worth $96,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $8.00, for a total transaction of $120,000.00. Following the transaction, the insider directly owned 1,685,426 shares in the company, valued at approximately $13,483,408. The trade was a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Johnson sold 135,400 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $7.22, for a total value of $977,588.00. Following the completion of the transaction, the director directly owned 698,083 shares in the company, valued at $5,040,159.26. This trade represents a 16.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 280,217 shares of company stock worth $2,041,841 in the last quarter. Company insiders own 4.56% of the company’s stock.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $7.36 on Tuesday. The stock has a market capitalization of $1.22 billion, a PE ratio of -73.59 and a beta of 0.52. The firm’s 50 day moving average price is $7.28 and its 200-day moving average price is $7.49. Xeris Biopharma Holdings, Inc. has a twelve month low of $3.44 and a twelve month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The business had revenue of $74.38 million for the quarter, compared to analyst estimates of $74.19 million. Analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on XERS shares. Zacks Research downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. Oppenheimer restated an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Piper Sandler boosted their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Finally, Barclays assumed coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Xeris Biopharma presently has a consensus rating of “Moderate Buy” and an average target price of $10.08.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.